1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

16. Brentjens RJ.CARs and cancers: questions and answers. Blood. 2012 Apr 26;119(17):3872-3.PMID:2253849317. How do CARs work? : Early insights from recent clinical studies targeting CD19.Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. Oncoimmunology. 2012 Dec 1;1(9):1577-1583.PMID: 23264903[PubMed]2. Abstracts (Optional, not encouraged)1. R. Brentjens, M. Gong, J.B. Latouche, I. Riviere, M. Sadelain. Long Term Survival of SCID-Beige Micebearing Raji Cell Tumors After Intravenous Treatment with Human T Cells Genetically Modified to Recognizethe CD19 Antigen [Abstract]. Blood. 2001; 98: 694a.2. R. Brentjens, J.B. Latouche, M. Weiss, I. Riviere, M. Sadelain. Genetic Modification of Peripheral Blood TCells from Patients with Chronic Lymphocytic Leukemia Results in Cytotoxic Activity Against AutologousTumor Cells [Abstract]. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002; 21: 276a.3. R. Brentjens, J.B. Latouche, I. Riviere, M. Weiss, M. Sadelain. Eradication of Systemic CD19+ Tumors inSCID-Beige Mice by Intravenous Treatment with Human CD8+ T Cells Genetically Modified to Recognize theCD19 Antigen [Abstract]. Mol. Ther. 2002; 5: S441. (ORAL PRESENTATION)4. R. Brentjens, J.B. Latouche, I. Riviere, M. Sadelain. In Vivo Anti-Tumor Activity of Genetically Modified TCells is Dependent on the Method of Ex Vivo T Cell Expansion [Abstract]. Blood. 2002; 100: 577a.5. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Riviere I,Sadelain M. Eradication of Systemic B cell Tumors by Genetically Targeted Human T Lymphocytes Co-Stimulated by CD80 and Interleukin-15 [Abstract]. Keystone Symposia 2003, Basic Aspects of TumorImmunology. Poster #439.6. R. Brentjens, M. Weiss, M. Sadelain. Genetic Modification of Autologous Peripheral Blood T Cells: AFeasible Immuno-Therapeutic Approach for the Treatment of Chronic Lymphocytic Leukemia (CLL)[Abstract]. 10 th International Workshop on CLL. Leuk. Lymph. 2003; 44(Supplement 2): S50. (ORALPRESENTATION)7. R. Brentjens, Y. Nikhamin, M. Matsushita, M. Sadelain. In Vitro and In Vivo Characterization of “Second-Generation” Co-Stimulatory Chimeric Antigen Receptors (CARs) Targeting the CD19 Antigen Present on BCell Malignancies [Abstract] Mol. Ther. 2005; 11: S311. (ORAL PRESENTATION)8. J. Stefanski, R. Brentjens, M. Bonyhadi, M. Sadelain, I. Rivière. Transduction and Expansion of TLymphocytes Genetically Engineered To Target the CD19 Antigen for the Treatment of CLL Using XcyteDynabeads®[Abstract] Mol. Ther. 2005; 11: S274.9. Lamanna, M. Kalaycio, P. Maslak, M. Heaney, R. Brentjens, J. Jurcic, E. Biederman, A. Gencarelli, K.Panageas, D. Sheinberg, M. Weiss. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has ComparableActivity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) inPatients with Previously Treated Chronic Lymphocytic Leukemia [Abstract]. Blood, 2005; 106: 601a.10. J. Stefanski, R. Brentjens, D. Hollyman, M. Bonyhadi, M. Sadelain, I. Riviere. CD19-Targeted Normal andCLL Patient T cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo. [Abstract]. Mol. Ther.2006; 13: S102.18